Localized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophin-associated proteins in mdx mice.
Bonuccelli, Gloria
Localized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophin-associated proteins in mdx mice. [electronic resource] - Cell cycle (Georgetown, Tex.) May 2007 - 1242-8 p. digital
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
1551-4005
10.4161/cc.6.10.4182 doi
Animals
Boronic Acids--pharmacology
Bortezomib
Dipeptides--pharmacology
Dystrophin--metabolism
Dystrophin-Associated Proteins--metabolism
Male
Mice
Mice, Inbred mdx
Microscopy, Fluorescence
Muscle, Skeletal--metabolism
Muscular Dystrophy, Duchenne--drug therapy
NF-kappa B--metabolism
Protease Inhibitors--pharmacology
Pyrazines--pharmacology
Localized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophin-associated proteins in mdx mice. [electronic resource] - Cell cycle (Georgetown, Tex.) May 2007 - 1242-8 p. digital
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
1551-4005
10.4161/cc.6.10.4182 doi
Animals
Boronic Acids--pharmacology
Bortezomib
Dipeptides--pharmacology
Dystrophin--metabolism
Dystrophin-Associated Proteins--metabolism
Male
Mice
Mice, Inbred mdx
Microscopy, Fluorescence
Muscle, Skeletal--metabolism
Muscular Dystrophy, Duchenne--drug therapy
NF-kappa B--metabolism
Protease Inhibitors--pharmacology
Pyrazines--pharmacology